HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Clinical trial NCT06595563 · RECRUITING
Trial details
- NCT number
- NCT06595563
- Sponsor
- Jules Bordet Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2028-03-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.